ALK | Allergy solutions for life
ALK

Allergy solutions for life

Take back control

More than 500 million people worldwide have allergies. Many of them suffer in silence because the way ahead is too confusing.

allergy_solutions_for_life

News

  • Post date
    02/24/2021
    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
  • Post date
    02/23/2021
    Annual General Meeting in ALK-Abelló A/S on 18 March 2021
  • Post date
    02/19/2021
    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
  • Post date
    02/10/2021
    ALK releases 2020 annual report
  • Post date
    02/04/2021
    Release date of annual report 2020 for ALK and audio cast
  • Post date
    12/17/2020
    ALK – Financial calendar for the 2021 financial year
  • Post date
    11/16/2020
    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
  • Post date
    11/11/2020
    Nine-month interim report (Q3) 2020
  • Post date
    11/06/2020
    Two new members of ALK’s Board of Directors
Strategy update: Focus areas during 2021-23
Having made the necessary, significant investments to transform ALK, we are now entering the next phase of the company’s development, where we must carefully work to sustain long-term growth, while also returning ALK to profitability.

Seasonal allergy symptoms can be confused with COVID-19

Therefore allergy symptoms should be kept under the best possible control. Watch Dr Glenis Scadding's expert advise in respect of seasonal allergies and COVID-19.

seasonal_allergic_rhinitis_in_relation_to_covid-19

ALK in brief

Allergy at a glance
Allergic rhinitis - popularly known as hay fever - is a widespread chronic disease. It is estimated to affect one in four persons in the industrialised world.
Our solutions
By collecting information and the latest and most trusted solutions together in one place, we want to make allergy surprisingly simple to manage.
Our heritage
Since 1923, we have consistently devised and developed major advances for the treatment of allergy. In recent years, we have invested substantially in the research and development of new, evidence-based allergy immunotherapy treatments.
Our responsibility
We aim to operate in a sustainable and ethical manner across our business and we underpin these aims with a range of policies and commitments.